Search

Author/Creator Miles, Kim

2. Systemic administration of IL‐33 induces a population of circulating KLRG1hi type 2 innate lymphoid cells and inhibits type 1 innate immunity against multiple myeloma. Issue 1 (18th September 2020)

Authors:
Guillerey, Camille; Stannard, Kimberley; Chen, Jason; Krumeich, Sophie; Miles, Kim; Nakamura, Kyohei; Smith, Jessica; Yu, Yuan; Ng, Susanna; Harjunpää, Heidi; Teng, Michele WL; Engwerda, Christian; Belz, Gabrielle T; Smyth, Mark J
Journal:
Immunology and cell biology
Issue:
Volume 99:Issue 1(2021)
Page Start:
65
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Targeting cytokine signaling checkpoint CIS activates NK cells to protect from tumor initiation and metastasis. (1st February 2017)

Authors:
Putz, Eva M.; Guillerey, Camille; Kos, Kevin; Stannard, Kimberley; Miles, Kim; Delconte, Rebecca B.; Takeda, Kazuyoshi; Nicholson, Sandra E.; Huntington, Nicholas D.; Smyth, Mark J.
Journal:
Oncoimmunology
Issue:
Volume 6:Number 2(2017)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗